Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party

• Published in: Leukemia Vol. 35; no. 9; pp. 2445 - 2459
• Main Authors: McLornan, Donal P., Hernandez-Boluda, Juan Carlos, Czerw, Tomasz, Cross, Nicholas, Joachim Deeg, H., Ditschkowski, Marcus, Moonim, Mufaddal T., Polverelli, Nicola, Robin, Marie, Aljurf, Mahmoud, Conneally, Eibhlin, Hayden, Patrick, Yakoub-Agha, Ibrahim
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.09.2021; Nature Publishing Group; Springer Nature
• Series: Leukemia
• Subjects: 692/699/1541; 692/699/1541/1990/2331; Adoptive immunotherapy; Best practice; Cancer Research; Care and treatment; Chimerism; Complications; Critical Care Medicine; Development and progression; Disease Management; Failure; Graft rejection; Graft Rejection - etiology; Graft Rejection - pathology; Graft Rejection - prevention & control; Graft vs Host Disease - etiology; Graft vs Host Disease - metabolism; Graft vs Host Disease - prevention & control; Grafting; Grafts; Hematology; Hematopoietic Stem Cell Transplantation - adverse effects; Humans; Immunotherapy; Inflammation; Intensive; Internal Medicine; Life Sciences; Medicine; Medicine & Public Health; Myelofibrosis; Oncology; Palliation; Practice Guidelines as Topic - standards; Primary Myelofibrosis - pathology; Primary Myelofibrosis - therapy; Recurrence; Review Article; Splenomegaly; Stem cells; Transplantation; Transplantation, Homologous; Transplants & implants; United Kingdom

Allogeneic haematopoietic cell transplantation (allo-HCT) remains the only curative approach in myelofibrosis (MF). Despite advances over recent decades, relapse and non-relapse mortality rates remain significant. Relapse rates vary between 15 and 25% across retrospective studies and management stra...